725 / DOI: 10.3332/ecancer.2017.725ecancer 11
The recent 58th Annual American Society of Haematology (ASH) meeting held in San Diego shed light on the usual mixture of groundbreaking basic and translational science and the recent practice-changing clinical trials. Recurrent themes this year were the use of recent next-generation sequencing (NGS) techniques to perfect prognostic stratification and disease monitoring. Newer prospects on the role of metabolism in normal and malignant haemopoiesis and mature data on long-awaited trials on immunotherapy and CAR-T cells in lymphoid neoplasms were also discussed.
Keywords: leukaemia, lymphoma, minimal residual disease, sequencing, clinical trial, CAR T cell
Loading Article Metrics ... Please wait
10 Jan 2017 / DOI: 10.3332/ecancer.2017.712Published:
05 Jan 2017 / DOI: 10.3332/ecancer.2017.710Published:
09 Nov 2016 / DOI: 10.3332/ecancer.2016.691Published:
02 Nov 2016 / DOI: 10.3332/ecancer.2016.688Published: